(NASDAQ: AVTX) Avalo Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 68.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.82%.
Avalo Therapeutics's earnings in 2026 is -$99,878,000.On average, 12 Wall Street analysts forecast AVTX's earnings for 2026 to be -$93,674,638, with the lowest AVTX earnings forecast at -$136,483,497, and the highest AVTX earnings forecast at -$35,225,233. On average, 8 Wall Street analysts forecast AVTX's earnings for 2027 to be -$75,910,603, with the lowest AVTX earnings forecast at -$121,555,614, and the highest AVTX earnings forecast at -$43,983,939.
In 2028, AVTX is forecast to generate -$62,426,185 in earnings, with the lowest earnings forecast at -$90,278,146 and the highest earnings forecast at -$35,796,453.